key: cord-263847-kyak5cy4
authors: Shi, Tzu-Hau; Huang, Yi-Long; Chen, Chiao-Che; Pi, Wen-Chieh; Hsu, Yu-Ling; Lo, Lee-Chiang; Chen, Wei-Yi; Fu, Shu-Ling; Lin, Chao-Hsiung
title: Andrographolide and its fluorescent derivative inhibit the main proteases of 2019-nCoV and SARS-CoV through covalent linkage
date: 2020-08-25
journal: Biochem Biophys Res Commun
DOI: 10.1016/j.bbrc.2020.08.086
sha: 
doc_id: 263847
cord_uid: kyak5cy4

The coronavirus disease 2019 (COVID-19) pandemic caused by 2019 novel coronavirus (2019-nCoV) has been a crisis of global health, whereas the effective vaccines against 2019-nCoV are still under development. Alternatively, utilization of old drugs or available medicine that can suppress the viral activity or replication may provide an urgent solution to suppress the rapid spread of 2019-nCoV. Andrographolide is a highly abundant natural product of the medicinal plant, Andrographis paniculata, which has been clinically used for inflammatory diseases and anti-viral therapy. We herein demonstrate that both andrographolide and its fluorescent derivative, the nitrobenzoxadiazole-conjugated andrographolide (Andro- NBD), suppressed the main protease (M(pro)) activities of 2019-nCoV and severe acute respiratory syndrome coronavirus (SARS-CoV). Moreover, Andro-NBD was shown to covalently link its fluorescence to these proteases. Further mass spectrometry (MS) analysis suggests that andrographolide formed a covalent bond with the active site Cys(145) of either 2019-nCoV M(pro) or SARS-CoV M(pro). Consistently, molecular modeling analysis supported the docking of andrographolide within the catalytic pockets of both viral M(pro)s. Considering that andrographolide is used in clinical practice with acceptable safety and its diverse pharmacological activities that could be beneficial for attenuating COVID-19 symptoms, extensive investigation of andrographolide on the suppression of 2019-nCoV as well as its application in COVID-19 therapy is suggested.

The outbreak of COVID-19, caused by a 2019-nCoV, is an urgent global health crisis which requires a timely solution. As end of July 2020, there are approximately eighteen million confirmed cases and seven hundred thousand deaths worldwide. Currently, the target-based therapeutics and effective treatment regimens for COVID-19 are still limited. One of the potential strategies is to target the proteins which are essential for life cycle of 2019-nCoV, such as main protease (M pro ) and papain-like protease (PL pro ) [1] . M pro is the viral protease involved in production of functional polyproteins required for viral replication, and no human homolog of this protein exists [2] . Remarkably, protein sequence of 2019-nCoV M pro is highly similar to that of the SARS-CoV M pro which is a proven target for reducing viral load of SARS [2, 3] . Therefore, 2019-nCoV M pro is a promising target for therapeutic intervention against COVID-19. Indeed, in vitro and in silico studies on identifying potential M pro inhibitors are rapidly growing in numbers [3] [4] [5] . Moreover, lopinavir/ritonavir, previously identified as HIV protease inhibitors and found to exhibit anti-SARS-CoV activity in vitro and in clinical, have been proposed to bind 2019-nCoV M pro and are being investigated for COVID-19 treatments [6, 7] . However, several clinical trials indicate that they have limited efficacy in treating COVID-19 and caused significant adverse effects, such as gastrointestinal intolerance and hepatotoxicity [8] .

Recently, a three-dimensional (3D) structure of 2019-nCoV M pro including the substrate-binding pocket has been illustrated [4] . In addition, M pro in SARS-CoV or 2019-nCoV is classified as a cysteine protease which involves an active site cysteine in its catalytic dyad. It has been shown that M pro could be inactivated by the inhibitors initiating a Michael addition reaction on the active site cysteine [2, 4] . Therefore, the Michael acceptor-containing compounds which can fit in the catalytic pocket of 2019-nCoV M pro may serve as attractive drug candidates for treating COVID-19.

Plant-derived natural products play crucial roles in new drug development [9] . Andrographolide, a lactone diterpenoid compound highly abundant in leaves of medicinal plant Andrographis paniculata, has been demonstrated to exhibit diverse pharmacological activities, including anti-inflammatory, anti-viral, anti-cancer and hepatoprotective effects [10] . Both A. paniculata extract and andrographolide alone are currently used worldwide for treating upper respiratory diseases as well as inflammatory diseases [10] [11] [12] . In addition, their clinical trials demonstrate that no significant adverse effects were observed in patients [10] [11] [12] . More importantly, andrographolide which contains a Michael acceptor group has been shown to react with the Cys 62 of NF-κB-p50 through covalent linkage [13, 14] , rendering it as a potential inhibitor of 2019-nCoV M pro . In this study, we investigated the inhibitory J o u r n a l P r e -p r o o f effects of andrographolide and its fluorescent derivative on the in vitro activity of 2019-nCoV M pro .

Andrographolide and disulfiram were purchased from Sigma-Aldrich (USA). Chemical syntheses of ANDRO-NBD and NCTU-048 were performed based on our previous studies [15, 16] . Sequencing grade chymotrypsin was obtained from Promega (USA).

Preparation of the recombinant SARS-CoV M pro was performed following a previous report [17] . Moreover, the DNA sequence of 2019-nCoV M pro was cloned into a pET-29a vector to encode recombinant protease with a C-terminal His 6 -tag. Upon plasmid transformation and IPTG induction in BL21 E. coli strain, the collected lysate supernatant was further purified by Ni-NTA affinity column (Qiagen, Germany) and S-100 size-exclusion chromatography column (GE Healthcare, USA) to produce pure 2019-nCoV M pro .

Activities of 2019-nCoV M pro and SARS-CoV M pro were measured following a previous cleavage assay which used a fluorogenic peptide substrate (Abz-TSAVLQSGFRK-Dnp) in phosphate buffered saline (PBS) buffer (20 mM, pH 7.6) at 30 o C for 3 min as [18] .

Upon the cleavage by protease, the quencher dinitrophenyl (Dnp) at C-terminal was released from the N-terminal fluorophore aminobenzoyl (Abz). Subsequently, the fluorescence at 423 nm was detected with excitation at 321 nm using a Perkin-Elmer LS 50B luminescence spectrometer (UK). The reaction concentrations of peptide substrate were ranged from 2 μM to 40 μM in PBS buffer (20 mM, pH 7.6), whereas the concentration of 2019-nCoV M pro and SARS-CoV M pro were respectively kept as 0.12 μM and 0.48 μM. Kinetics parameters like K m and k cat were determined by fitting the initial velocities at different substrate concentrations to a Michaelis-Menten equation, as described previously [18] .

To determine inhibition of M pro activity, inhibitor (0 μM to 20 μM) and fluorogenic peptide substrate (5 μM) in PBS buffer (20 mM, pH 7.6) were first equilibrated at μM SARS-CoV M pro ) and further incubation at 30 o C for 3 min. As described above, enzymatic activity was determined and the measured velocities at different inhibitor concentrations were fitted to obtain IC 50 according to the following equation:

in which ν is the velocity with incubation of inhibitor at different concentration [I] and the v 0 is the initial velocity without incubation of inhibitor, while n is the Hill constant.

A total of 3 μM M pro was treated with Andro-NBD in various molar ratios at 25 o C for 1 h and then analyzed by 12% SDS-PAGE. The resulting polyacrylamide gels were scanned for fluorescence at 520 nm under excitation at 488 nm using Amersham Imager 680 (GE healthcare, USA).

The 3D structures of viral main protease were downloaded from the protein data bank (PDB, https://www.rcsb.org) which collects the published X-ray structures of SARS-CoV M pro and 2019-nCoV M pro [4, 19] . Water molecules, ions, co-crystalized ligand were first removed from original structure prior to docking experiment, and chemical structure of andrographolide was added. The resulted complex of protein/andrographolide was subjected to molecular docking using Arguslab 4.0.1 to evaluate the putative ligand-binding site and release of free energy [20] . The optimal docking sites for ligand were accordingly predicted.

All of the data were represented as the mean ± standard derivation (SD) from three independent experiments. * represents p-value <0.05; ** represents p-value <0.01; *** represents p-value <0.001 by Student's t-test.

Recent genome analysis of 2019-nCoV revealed the organization of its open reading frame 1 (ORF1) which encodes two polyproteins consisting of all the non-structural proteins needed for virus replication and is very similar to SARS-CoV [21, 22] (Fig. S1 ).

In addition, sequence alignment of main proteases from 2019-nCoV, SARS-CoV and whereas the identity between 2019-nCoV M pro and MERS-CoV M pro is only 51% (Fig.  S2 ). Because M pro is the essential protease which is responsible to produce the individual non-structural proteins upon proteolytic cleavage on the primary polyproteins, we further aligned amino acid sequences of all the 12 cleavage sites by 2019-nCoV M pro (Fig. S3A ). Among these sites, 8 of them are completely conserved between 2019-nCoV M pro and SARS-CoV M pro , including the peptide sequence between nsp4 and nsp5 (-TSITSAVLQSGFRKMAFP-) (Fig. S3B) . Previously, a fluorogenic peptide (Abz-TSAVLQSGFRK-Dnp) which contains both a fluorophore (Abz) and its quencher (Dnp), has been used to determine the protease activity of SARS-CoV M pro (Fig. S3C ) [23] . Upon the cleavage of this peptide probe by protease, the fluorophore (Abz) was separated from its quencher and thus emitted fluorescence under UV excitation. We therefore prepared the recombinant 2019-nCoV M pro and SARS-CoV M pro , and measured their protease activities using this fluorogenic probe (Fig. 1A) . Results of the protease activity assay revealed that 2019-nCoV M pro exhibits higher activity and catalytic efficiency than SARS-CoV M pro ( Fig. 1B and Table 1 ).

SARS-CoV M pro was previously shown to function in a dimeric form. We therefore measured the continuous sedimentation coefficient distribution using analytical ultracentrifugation (AUC) to determine whether 2019-nCoV M pro forms a homodimer (Fig. 1C) . The profiles of quaternary structure at different concentrations suggest that 2019-nCoV M pro exists predominantly in a dimeric structure (Fig. 1D) , using SARS-CoV M pro as a reference (Fig. 1E ). In addition, SARS-CoV M pro was previously shown to increase its monomeric form when existed in acidic environment [23] .

However, further AUC experiments of 2019-nCoV M pro under acidic condition (pH 6) only slightly increased its monomeric ratio. (Fig. S4 ).

Andrographolide has been reported to inhibit protein function through a Michael addition reaction with the free thiol side chain of cysteine [13, 14] . We thus further M pro in a Michael addition-dependent manner, a thiol-insensitive andrographolide derivative (NCTU-048) was also examined in the protease activity assay and it exhibited relatively low protease inhibition (Fig. 2C) . Moreover, a previously reported SARS-CoV M pro inhibitor (disulfiram) was also investigated for its inhibition on 2019-nCoV M pro and the result showed an IC 50 of 5.61±0.34 μM (Fig. 2D ).

As described above, both andrographolide and Andro-NBD were shown to inhibit the activity of 2019-nCoV M pro . We have previously demonstrated that Andro-NBD forms a covalent bond with p50 subunit of NF-kB [15] . Whether Andro-NBD also inhibits 2019-nCoV M pro through a covalent linkage was herein investigated. As shown in 

We further carried out the docking experiment using Arguslab modeling program [20] to study whether andrographolide enters the catalytic pockets of 2019-nCoV M pro (PDB 6LU7) and SARS-CoV M pro (PDB 1UK4) [4, 22] . As shown in Fig. 4A estimated to be -9.72 kcal/mol (ΔG) and the distance between Cys 145 and the acceptor carbon of Michael reaction (C12 of andrographolide) is 3.7Å (Fig. 4B and  4C) . Similarly, SARS-CoV M pro exhibits comparable binding affinity of andrographolide at -7.85 kcal/mol and its Cys 145 is 4.8Å away from Michael addition site (Fig. 4E and  4F) . Together, these results support our findings of andrographolide-mediated inhibition and covalent linkage of 2019-nCoV M pro and SARS-CoV M pro .

Our results demonstrated that andrographolide can inhibit the activity of 2019-nCoV M pro (IC 50 = 15.05±1.58 µM; Fig. 2A ). Molecular modeling data further support that andrographolide can enter the proposed substrate-binding pocket of 2019-nCoV M pro (Fig. 4) , such observation is consistent with a recent in silico study suggesting that andrographolide can dock in the binding site of 2019-nCoV M pro [24] .

Furthermore, we also found that Andro-NBD, but not compound 048, strongly inhibited the activity of 2019-nCoV M pro (IC 50 = 2.79 ±0.3 µM for Andro-NBD; > 240 µM for NCTU-048) (Fig. 2) . 2019-nCoV M pro is a cysteine protease known to be inactivated by Michael acceptor inhibitor N3 [4] . Andrographolide belongs to the Michael acceptor category of electrophilic natural compounds and it has been reported to react with Cys62 of NF-κB-p50 at C12-13 exocyclic double bond to form a covalent adduct through a Michael addition [13, 14] . Andro-NBD also can covalently bond to the p50, presumably through a similar mechanism [15] . On the other hand, the compound NCTU-048 with much weaker bioactivity than andrographolide is suggested to interact with NF-κB-p50 through different mechanism [25] . Accordingly, Andro-NBD was shown capable of forming covalent linkage with 2019-nCoV M pro , whereas C145A mutation of protease abolished such covalent bond (Fig. 3) . Furthermore, MS-based sequencing analysis suggested that andrographolide forms a covalent bond with active site Cys 145 of 2019-nCoV M pro (Fig.  S6) . Notably, such covalent linkage of andrographolide with reactive cysteine of protein target has also been reported previously [26] . Together, our data support a model that Andro and Andro-NBD could enter the substrate-binding pocket and initiate Michael reaction with 2019-nCoV M pro , leading to the inactivation of protease activity.

Lopinavir/ritonavir, the HIV protease inhibitors previously identified with anti-SARS-CoV activity in vitro and in clinical, was proposed to bind 2019-nCoV M pro and thus has been investigated for COVID-19 treatments [6, 7] . Currently, inhibition of 2019-nCoV by Lopinavir/ritonavir has not been experimentally demonstrated.

Data of several clinical trials indicate their roles in treating COVID-19 are limited and their significant adverse effects, such as gastrointestinal intolerance and hepatotoxicity, have been observed [8] . Disulfiram, an FDA-approved drug for treating alcohol addiction, has been reported to inhibit 2019-nCoV M pro [4] but its clinical efficacy against COVID-19 remains to be determined. Therefore, development of 2019-nCoV M pro inhibitors from clinically available medicine is still in great demand.

Andrographis paniculata along with its major ingredient, andrographolide, have been used as herbal medicine for treating anti-inflammatory diseases in Asia and in Europe [10] . Accumulating evidences from clinical studies indicate that Andrographis paniculata extract and andrographolide reduce symptoms in patients with HIV, upper respiratory infection, ulcerative colitis or rheumatoid arthritis with considerable safety [10, [27] [28] [29] [30] . Furthermore, experimental data from preclinical studies demonstrated the diverse pharmacological mechanisms of A. paniculata and andrographolide, including those in anti-inflammation, antiviral activity, hepatoprotection, anti-pulmonary fibrosis, and cardiopretection [10, 12, [31] [32] [33] Particularly, their safety profile in clinical uses are well accepted and andrographolide up to 30 µM did not cause cytotoxicity on human peripheral blood mononuclear cells (PBMC) [10, 34] .

In this study, we revealed that andrographolide and its derivative inhibits the activity of main protease and thus likely to impair the replication of SARS-CoV and 2019-nCoV. Considering that andrographolide is widely demonstrated in clinical application with acceptable safety and exhibits diverse pharmacological activities which could be beneficial for attenuating COVID-19 symptoms, application of andrographolide on COVID-19 therapy certainly merit further investigation. 

Therapeutic options for the 2019 novel coronavirus (2019-nCoV)

An Overview of Severe Acute Respiratory Syndrome-Coronavirus (SARS-CoV) 3CL Protease Inhibitors: Peptidomimetics and Small Molecule Chemotherapy

Learning from the Past: Possible Urgent Prevention and Treatment Options for Severe Acute Respiratory Infections Caused by 2019-nCoV

Structure of M(pro) from COVID-19 virus and discovery of its inhibitors

Structural basis of SARS-CoV-2 3CL(pro) and anti-COVID-19 drug discovery from medicinal plants

Discovering drugs to treat coronavirus disease 2019 (COVID-19)

Why Are Lopinavir and Ritonavir Effective against the Newly Emerged Coronavirus

Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review

Natural Products as Sources of New Drugs from 1981 to

Overview of pharmacological activities of Andrographis paniculata and its major compound andrographolide

Plant-derived immunomodulators: an insight on their preclinical evaluation and clinical trials

Experimental and Clinical Pharmacology of Andrographis paniculata and Its Major Bioactive Phytoconstituent Andrographolide

Electrophilic natural products and their biological targets

Andrographolide attenuates inflammation by inhibition of NF-kappa B activation through covalent modification of reduced cysteine 62 of p50

Development of a Bifunctional Andrographolide-Based Chemical Probe for Pharmacological Study

Andrographolide downregulates the v-Src and Bcr-Abl oncoproteins and induces Hsp90 cleavage in the ROS-dependent suppression of cancer malignancy

Mutation of Glu-166 blocks the substrate-induced dimerization of SARS coronavirus main protease

Correlation between dissociation and catalysis of SARS-CoV main protease

Coronavirus main proteinase (3CLpro) structure: basis for design of anti-SARS drugs

Detailed comparison of the protein-ligand docking efficiencies of GOLD, a commercial package and ArgusLab, a licensable freeware

A new coronavirus associated with human respiratory disease in China

Unique and conserved features of genome and proteome of SARS-coronavirus, an early split-off from the coronavirus group 2 lineage

Quaternary structure of the severe acute respiratory syndrome (SARS) coronavirus main protease

Andrographolide As a Potential Inhibitor of SARS-CoV-2 Main Protease: An In Silico Approach

Specificity and inhibitory mechanism of andrographolide and its analogues as antiasthma agents on NF-kappaB p50

A quantitative chemical proteomics approach to profile the specific cellular targets of andrographolide, a promising anticancer agent that suppresses tumor metastasis

Andrographolide drop-pill in treatment of acute upper respiratory tract infection with external wind-heat syndrome: a multicenter and randomized controlled trial

Efficacy of an Andrographis paniculata composition for the relief of rheumatoid arthritis symptoms: a prospective randomized placebo-controlled trial

A phase I trial of andrographolide in HIV positive patients and normal volunteers

Andrographis paniculata extract (HMPL-004) for active ulcerative colitis

Broad-spectrum antiviral properties of andrographolide

Restoration of HDAC2 and Nrf2 by andrographolide overcomes corticosteroid resistance in chronic obstructive pulmonary disease

Protective role of andrographolide in bleomycin-induced pulmonary fibrosis in mice

Andrographolide and its potent derivative exhibit anticancer effects against imatinib-resistant chronic myeloid leukemia cells by downregulating the Bcr-Abl oncoprotein

We specifically thank Dr. Chi-Yuan Chou from the Department of Life Sciences at National Yang-Ming University for providing the SARS-CoV M pro , the fluorogenic peptide probe and the technical assistance of AUC. We also thank Dr. Chen-Chung Liao of Proteomics Research Center at National Yang-Ming University for the technical assistance of MS analysis and data processing. The authors declare no conflicts of interest.J o u r n a l P r e -p r o o f